Drug intelligence / Profile preview

AZD7053

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Subcutaneous[1][2][4]

Overview

AZD7053 is an investigational drug developed by AstraZeneca. It is currently being evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics following multiple subcutaneous doses in healthy Japanese participants. The specific mechanism of action for AZD7053 has not been disclosed publicly as of June 2025. There are no approved indications or known adverse events reported for this compound at this time[1][2][3][4]. The drug is not yet approved for any indication and remains under early-stage clinical investigation.

Beyond the preview

Go deeper on AZD7053.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD7053.

Explore the full profile